Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial
6d ago1 min readNews
From the article
Savolitinib shows promise for MET^amp^ gastric/GEJ cancer: Phase 2 data reveal potential as a targeted therapy in this poor prognosis group. PMID:42225990, Nat Med 2026, @NatureMedicine #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
Continue reading on doi.orgYou might also wanna read
Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study
clinicaltrials.gov·3d ago
Sac-TMT Combined With Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
clinicaltrials.gov·1d ago
Phase Ib/IIa Open-label Study, to Evaluate Safety, Tolerability, and Antitumor Activity of HCB101 in Combination With Multiple Agents in Subjects With Advanced Gastric or Gastro-esophageal (GEJ) Adenocarcinoma
clinicaltrials.gov·7d ago
Personalized Treatment Strategies for HER2-Positive Gastroesophageal Adenocarcinoma
This article discusses evolving strategies for personalized treatment of HER2-positive gastroesophageal adenocarcinoma (GEA). It features in
mdsc.pe·19d agoBecotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II
clinicaltrials.gov·2d ago
A Phase II Study of PD-1/IL-2α-bias Bispecific Antibody Fusion Protein Monotherapy in Advanced Esophageal Squamous Cell Carcinoma After Failure of Prior ICI Plus Platinum-Based Chemotherapy
clinicaltrials.gov·2d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.